DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Brown syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrown syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brown syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Three siblings in one family developed unilateral left-sided Brown syndrome at 12–13 years of age, worse on awakening, with no abnormalities of the trochlear-tendon complex detected on imaging. Haplotype analysis was consistent with either recessive inheritance at the DURS1 locus or dominant inheritance with reduced penetrance at the DURS1, DURS2, and FEOM1 loci. No mutations were found in the CFEOM2 gene, ARIX. The authors concluded that a genetically determined predisposition is likely, but the pattern of inheritance could not be definitively assigned, and only the FEOM3 locus and ARIX gene could be excluded.
Congenital Brown syndrome may be related to neurodevelopmental abnormalities of the extraocular muscles, grouped under congenital cranial dysinnervation disorders (CCDD). This category includes conditions such as congenital fibrosis of the extraocular muscles, Duane syndrome, and Moebius syndrome. It has been suggested that some cases of congenital Brown syndrome and congenital superior oblique paresis are related and may fall within the CCDD spectrum. The cause of congenital Brown syndrome remains unknown, though some familial cases have been described.
Spontaneous resolution occurs in 20 to 30% of congenital cases. Conservative management is successful in around 75% of cases. Inflammatory acquired Brown syndrome may respond to peri-trochlear steroid injection or oral non-steroidal anti-inflammatory agents. Surgical management has been undertaken, but results are described as disappointing.
What is still missing is a clear genetic or developmental mechanism for most cases, prospective data on which patients will resolve spontaneously, and a surgical approach that reliably improves elevation in adduction without causing new restrictions or overcorrections.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ophthalmic Genetics · 2002 · 15 citations
Familial unilateral Brown syndrome
AbstractPURPOSE: To report a family in which three siblings have unilateral late-onset Brown syndrome. METHODS: The entire nuclear family underwent ophthalmologic evaluation. Orbital imaging and systemic workup were obtained to rule out local or systemic causes. Historic information was obtained from unavailable family members. The family's Brown syndrome trait was analyzed for linkage to the known congenital fibrosis syndrome loci and the CFEOM2 gene, ARIX, was sequenced in affected individuals. RESULTS: All affected siblings developed left-sided Brown syndrome, worse on awakening, at 12-13 years of age. No evidence of Brown syndrome could be identified in other family members, either by exam or history. No abnormalities of the trochlear-tendon complex could be documented. Haplotype analysis of the Brown syndrome phenotype was consistent with recessive inheritance at the DURS1 locus and dominant inheritance with reduced penetrance at the DURS1, DURS2, and FEOM1 loci. No mutations were detected in CFEOM2 gene, ARIX. CONCLUSIONS: We propose that a genetically determined predisposition to Brown syndrome is likely responsible for the observed manifestations in this family and that late age of onset and intermittent manifestations do not distinguish acquired from hereditary Brown syndrome. The pattern of inheritance of the Brown phenotype in this family could be either autosomal recessive or autosomal dominant with reduced penetrance. Our analysis only permitted the exclusion of the FEOM3 locus and the FEOM2 gene, ARIX. Future genetic studies of additional Brown syndrome families should shed additional light on the genetic basis of this disorder.
Current Opinion in Ophthalmology · 2015 · 14 citations
Considerations on the etiology of congenital Brown syndrome
AbstractPURPOSE OF REVIEW: Brown syndrome is an ocular motility disorder characterized by limited volitional and passive elevation of the eye in adduction. Although originally thought due to abnormalities in the trochlea or tendon sheath (limiting the free movement of the tendon through the trochlea), recent evidence suggests that some cases of congenital Brown syndrome may be related to neurodevelopmental abnormalities of the extraocular muscles (congenital cranial dysinnervation disorders, CCDD). RECENT FINDINGS: CCDD is a term encompassing congenital abnormalities of eye movements caused by congenital innervational abnormalities. The abnormal development of cranial nerve nuclei or abnormalities in cranial nerve axonal transport affects the development of the extraocular muscle(s). Currently, congenital fibrosis of the extraocular muscles, Duane syndrome, Moebius syndrome, Horizontal gaze palsy and progressive scoliosis, and synergistic divergence are included as CCDDs. In addition, congenial ptosis, Jaw Wink ptosis, and congenital superior oblique palsy are also included. Recently, it has been suggested that some cases of congenital Brown syndrome and congenital superior oblique paresis are related, and these entities may be part of the CCDDs spectrum. SUMMARY: Important findings regarding the cause of congenital Brown syndrome will be reviewed.
AbstractBrown syndrome is a challenging management problem. Congenital Brown syndrome may show spontaneous resolution, and conservative management is successful in around 75% of cases. Inflammatory acquired Brown syndrome may respond to peri-trochlear injection of steroids or oral non-steroidal inflammatory agents. Post-traumatic acquired Brown syndrome is not as common as it was in the "pre-seat belt" era. Surgical management can be undertaken, but results are disappointing.
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 2017 · 0 citations · open access
Ophthalmology case
AbstractBrown syndrome is a rare ocular motility abnormality characterized by a restriction of the superior oblique tendon, which results in a restriction of elevation in adduction. This entity can be congenital or acquired. The cause of congenital Brown`s syndrome remains unknown but some cases with a family history have been described. Spontaneous resolution occurs between 20 to 30%. We describe a case of an eight-year-old boy with congenital Brown syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
